Compare Natera Inc. Common Stock (NTRA) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Paychex, Inc. — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Paychex, Inc. trades at $108.92 (market cap $37.82B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Paychex, Inc. pays a 4.48% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Paychex, Inc. for 56 Days on average.
| NTRA | PAYX | |
|---|---|---|
Market Cap | $57.03B | $37.82B |
Volume | 1,131,157 | 2,018,238 |
Sector | Health | Industrials |
52-Week High | $425.64 | $127.54 |
52-Week Low | $179.42 | $85.57 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $56.18B | $41.51B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Paychex (PAYX) trades at $108.37, up 3.56% today, with mixed technical signals showing bullish overall momentum but bearish moving averages. The company maintains strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.34 beating $1.32 estimates, and robust profitability metrics including 27.35% net income margin and 47.06% ROE. Recent news highlights dividend safety concerns despite the company's 5-star rating on Newsweek's America's Greatest Companies 2026 list.
Outlook remains cautiously optimistic with analyst consensus target of $111 suggesting modest upside, though high valuation multiples (P/E 21.08, P/S 5.77) and competitive pressures in payroll services present risks. The stock offers income potential with recent $1.19 dividend, but investors should monitor PEO segment performance and labor market trends affecting small business clients.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
